Cargando…

Transformation from Small Cell to Squamous Cell Carcinoma in a Thymic Carcinoma Patient with a Durable Response to Anlotinib: A Case Report

The most common pathologic type of thymic carcinoma (TC) is squamous cell carcinoma (SCC). Small cell carcinoma is relatively rare, accounting for approximately 2% to 5% of all thymic tumors. Histologic transformation of TC has not yet been reported. Available treatments for TC patients who progress...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Wenru, Zou, Bing, Fan, Xinyu, Fan, Bingjie, Wang, Shijiang, Wang, Linlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063945/ https://www.ncbi.nlm.nih.gov/pubmed/35521088 http://dx.doi.org/10.2147/CMAR.S362858

Ejemplares similares

Prophylactic cranial irradiation-related lymphopenia affects survival in patients with limited-stage small cell lung cancer
por: Fan, Xinyu, et al.
Publicado: (2023)

A novel deep learning prognostic system improves survival predictions for stage III non‐small cell lung cancer
por: Yang, Linlin, et al.
Publicado: (2022)

Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review
por: Zuo, Ran, et al.
Publicado: (2020)

Thymic squamous cell carcinoma in a cat
por: Looi, Richard Chung Yi, et al.
Publicado: (2022)

Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs
por: Mu, Fengchun, et al.
Publicado: (2023)

Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
por: Shi, Jingzhen, et al.
Publicado: (2020)

Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma
por: Jiang, Bailing, et al.
Publicado: (2019)

The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma
por: Song, Yan, et al.
Publicado: (2021)

Corrigendum: Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
por: Shi, Jingzhen, et al.
Publicado: (2020)

Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
por: Chen, Si-Cong, et al.
Publicado: (2023)

An unusual combined thymic carcinoma composed of squamous cell carcinoma and type AB thymoma: a rare case report
por: Jiang, Yufeng, et al.
Publicado: (2017)

(18)F-deoxyglucose positron emission tomography/computed tomography to predict local failure in esophageal squamous cell carcinoma
por: Fan, Bingjie, et al.
Publicado: (2017)

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib
por: Sato, Mitsuo, et al.
Publicado: (2018)

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial
por: Huang, Jing, et al.
Publicado: (2021)

Anlotinib as a promising inhibitor on tumor growth of oral squamous cell carcinoma through cell apoptosis and mitotic catastrophe
por: Deng, Zhaoming, et al.
Publicado: (2021)

Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer
por: Qin, Wenru, et al.
Publicado: (2022)

Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report
por: Chen, Cui, et al.
Publicado: (2022)

Using Patient-Derived Xenografts to Explore the Efficacy of Treating Head-and-Neck Squamous Cell Carcinoma With Anlotinib
por: Hu, Fangling, et al.
Publicado: (2021)

Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis
por: Zhen, Hongchao, et al.
Publicado: (2023)

METTL3 suppresses anlotinib sensitivity by regulating m(6)A modification of FGFR3 in oral squamous cell carcinoma
por: Chen, Jie, et al.
Publicado: (2022)

The incidence and prognosis of thymic squamous cell carcinoma: A Surveillance, Epidemiology, and End Results Program population-based study
por: Wu, Jingyi, et al.
Publicado: (2021)

Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer
por: Li, Butuo, et al.
Publicado: (2022)

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
por: Liu, Ying, et al.
Publicado: (2022)

Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study
por: Zhang, Song, et al.
Publicado: (2022)

Multiple Immune Features-Based Signature for Predicting Recurrence and Survival of Inoperable LA-NSCLC Patients
por: Guo, Meiying, et al.
Publicado: (2020)

Anti-Apoptotic Signature in Thymic Squamous Cell Carcinomas – Functional Relevance of Anti-Apoptotic BIRC3 Expression in the Thymic Carcinoma Cell Line 1889c
por: Huang, Bei, et al.
Publicado: (2013)

AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
por: Wang, Chang-Lu, et al.
Publicado: (2022)

Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review
por: Liu, Zichang, et al.
Publicado: (2023)

Thymic Squamous Cell Carcinoma: A Population-Based Surveillance, Epidemiology, and End Result Analysis
por: Yang, Xudong, et al.
Publicado: (2020)

Ectopic cervical thymic squamous cell carcinoma misdiagnosed as thyroid cancer: a case report
por: Kim, Ju-Yeon, et al.
Publicado: (2022)

CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets
por: Kashima, Jumpei, et al.
Publicado: (2022)

Skeletal muscle and related protein expression as prognostic factors in thymic squamous cell carcinoma
por: Nakanishi, Keita, et al.
Publicado: (2022)

Squamous cell carcinoma with sarcomatous transformation of the penis
por: dos Santos, Joana, et al.
Publicado: (2021)

A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019)

A Rare Case of a High-Grade Thymic Squamous Cell Carcinoma Presenting as Cardiac Tamponade
por: Rai, Maitreyee, et al.
Publicado: (2020)

A Case Report of Targeted Therapy with Anlotinib in a Patient with Advanced Breast Metaplastic Carcinoma
por: Zou, Jieya, et al.
Publicado: (2021)

AIRE illuminates the feature of medullary thymic epithelial cells in thymic carcinoma
por: Matsumoto, Minoru, et al.
Publicado: (2023)

A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report
por: Gui, Lin, et al.
Publicado: (2021)

Hepatoid thymic carcinoma: a case report of a rare subtype of thymic carcinoma
por: Jeong, Ji-Seon, et al.
Publicado: (2021)

A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma
por: Li, Ning, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4jm2dtvjrblcipj7kpnkt91u0a